Pharmaceuticals company Emcure Pharmaceuticals announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from operations at Rs 2,116 crore, up 19.5% YoY EBITDA margins at 18.4% with EBITDA up 25.2% YoY PAT at 197 crore, up 63.0% YoY Domestic business sales at 929 crore, up 24.8% YoY International business sales at 1,187 crore, up 15.6% YoY The Board has proposed a final dividend of Rs 3/- per share FY25 Financial Highlights: Revenue from Operations stood at Rs 7,896 crore for FY25 compared to Rs 6,658 crore FY24 up 18.6% EBITDA stood at Rs 1,469 crore for FY25 compared to Rs 1,230 crore for FY24 up 19.4% PAT at Rs 707 crore for FY25 compared to Rs 528 crore for FY24 up 34.1% Commenting on the results, Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals, said, “Emcure delivered a very strong performance in Q4 with all our businesses segments contributing to growth. Over the past year we have effectively executed our strategies across both Domestic and International markets. On the Domestic side we have expanded our covered market and built a strong product pipeline of upcoming launches. In the International markets we are seeing approvals for our differentiated product offerings. Moving forward, while we continue to drive growth, our key priorities will be improving margins through new product launches and operating efficiencies.” Result PDF
Conference Call with Emcure Pharmaceuticals Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Emcure Pharmaceuticals announced Q3FY25 results Revenue: Rs 1,963 crore compared to Rs 1,668 crore during Q3FY24, change 17.7%. EBITDA: Rs 362 crore compared to Rs 294 crore during Q3FY24, change 23.2%. EBITDA Margins: 18.4% for Q3FY25. PAT: Rs 156 crore compared to Rs 120 crore during Q3FY24, change 30.3%. PAT margin: 8.0% for Q3FY25. Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals, said: “Emcure witnessed a strong performance in Q3. Our International business is seeing strong performance on back of our differentiated product portolio. On the domestic side, our focus is on expanding our covered market through differentiated product launches and driving synergies from the in-licensed Sanofi portolio. Moving forward, we aim to enhance our organic growth and margins through new product launches and operating efficiencies.” Result PDF